Brookline Capital Management Estimates CervoMed Q2 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Brookline Capital Management issued their Q2 2025 EPS estimates for shares of CervoMed in a note issued to investors on Tuesday, March 11th. Brookline Capital Management analyst T. Bussian expects that the company will earn ($0.48) per share for the quarter. Brookline Capital Management currently has a “Hold” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q3 2025 earnings at ($0.38) EPS.

CRVO has been the subject of a number of other reports. Roth Mkm increased their price objective on shares of CervoMed from $7.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of CervoMed in a report on Tuesday. Morgan Stanley reaffirmed an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. Chardan Capital reaffirmed a “neutral” rating on shares of CervoMed in a report on Wednesday, December 11th. Finally, HC Wainwright cut shares of CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, CervoMed currently has an average rating of “Moderate Buy” and an average price target of $33.14.

CervoMed Stock Performance

CervoMed stock opened at $6.17 on Wednesday. The firm has a 50-day moving average of $2.30 and a 200-day moving average of $8.20. CervoMed has a one year low of $1.80 and a one year high of $26.38.

Institutional Trading of CervoMed

Several large investors have recently made changes to their positions in the company. Citizens Financial Group Inc. RI boosted its position in shares of CervoMed by 13.2% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock worth $445,000 after acquiring an additional 3,553 shares in the last quarter. FMR LLC acquired a new stake in shares of CervoMed during the 3rd quarter worth approximately $56,000. Barclays PLC boosted its position in shares of CervoMed by 323.6% during the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after acquiring an additional 5,919 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of CervoMed by 251.8% during the 4th quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after acquiring an additional 10,352 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of CervoMed during the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.